<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intravenous administration of human bone marrow stromal cells (hMSCs) after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAo) in rats provides functional benefit </plain></SENT>
<SENT sid="1" pm="."><plain>We tested the hypothesis that these functional benefits are derived in part from hMSC production of growth and trophic factors </plain></SENT>
<SENT sid="2" pm="."><plain>Quantitative sandwich enzyme-linked immunosorbent assay (ELISA) of hMSCs cultured with <z:mpath ids='MPATH_458'>normal</z:mpath> and MCAo brain extracts were performed </plain></SENT>
<SENT sid="3" pm="."><plain>hMSCs cultured in supernatant derived from ischemic brain extracts increased production of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) </plain></SENT>
<SENT sid="4" pm="."><plain>These neurotrophins and angiogenic growth factors increased in a post-<z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> time-dependent manner </plain></SENT>
<SENT sid="5" pm="."><plain>The hMSC capacity to increase expression of growth and trophic factors may be the key to the benefit provided by transplanted hMSCs in the ischemic brain </plain></SENT>
</text></document>